ESTRO 2025 - Abstract Book

S1696

Clinical - Sarcoma & skin cancer & malignant melanoma

ESTRO 2025

Results: Median follow-up was 13.2 months (range 3.3-39.0). The median D95% for the GTV was 61.8 Gy (IQR 59.0-62.3) in tumours prescribed 63 Gy, 68.2 Gy (IQR 66.4-68.78) in bone tumours prescribed 70 Gy, and 61.7 Gy (IQR 59.1-64.2) for other dose prescriptions. At 12 months, local control was 90% for soft tissue tumours and 89% for bone tumours, progression-free survival was 58% and 61%, and overall survival was 91% and 83% respectively ( Figure 1 ). For the 45 patients (74%) without distant disease at the time of radiotherapy, metastasis-free survival at 12 months was 73% for soft tissue tumours and 86% for bone tumours.